Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.04M in total
- 5
- 13F holdersQ2 2026, +20 vs. previous quarter
- 199
- 13F valueReported value at the end of Q2 2026
- $1.06B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding REPL, Q2 2026
No superinvestor reported holding REPL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Replimune Group, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)6:42 PM ET | Aug 17 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −9.26K | $14.28 | −$132.2K | −4.1%215.9K after | |
| Aug 12, 2026 (view filing)5:07 PM ET | Aug 10 | 2 days | Patel SushilChief Executive Officer | SSale | −39.3K | $12.97 | −$510.3K | −5.3%708.2K after | |
| Aug 12, 2026 (view filing)5:06 PM ET | Aug 10 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.8%225.1K after | |
| Aug 12, 2026 (view filing)5:05 PM ET | Aug 10 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.9%224.2K after | |
| Aug 12, 2026 (view filing)5:04 PM ET | Aug 10 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −7.63K | $12.97 | −$99.0K | −7.1%99.4K after | |
| Aug 11, 2026 (view filing)5:46 PM ET | Aug 11 | Same day | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.74M | $12.06 | +$33.0M | –2.61M after | Derivative2 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −12.0K | $9.24 | −$110.9K | −6.2%181.0K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −14.0K | $5.08 | −$71.2K | −5.6%235.7K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −7.89K | $5.08 | −$40.1K | −6.9%107.1K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −8.63K | $5.08 | −$43.8K | −4.3%193.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Replimune Group, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 11,045,336 | $122.3M | 0.61% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,958,535 | $99.2M | 0.00% | +2,719,296+43.6% | Added |
| RTW Investments, LP | 7,411,581 | $82.0M | 0.70% | +54,665+0.7% | Added |
| Ridgeback Capital Investments L.P. | 7,310,656 | $80.9M | 100.00% | +7,310,656 | New |
| Goldman Sachs Group Inc | 4,541,018 | $50.3M | 0.01% | +2,263,742+99.4% | Added |
| State Street Corp | 4,440,144 | $49.2M | 0.00% | +657,907+17.4% | Added |
| Suvretta Capital Management, LLC | 4,389,836 | $48.6M | 1.02% | +168,000+4.0% | Added |
| Boxer Capital Management, LLC | 3,983,000 | $44.1M | 3.32% | +2,808,000+239.0% | Added |
| Vanguard Capital Management LLC | 2,896,004 | $32.1M | 0.00% | +136,884+5.0% | Added |
| FCPM III Services B.V. | 2,808,368 | $31.1M | 4.14% | 00.0% | Unchanged |
Holders of 5% or more of REPL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Replimune Group, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 13D | 14.30%11.0M shares | New | Mar 7, 20251 filing | Mar 7, 2025 | SEC |
| Forbion Capital Fund III Cooperatief U.A. | 13G/A | 6.10%4.22M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |